Garmin vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Olathe KS GPS and wearables (NASDAQ: GRMN) $6.3B FY2024 revenue (+18%); auto OEM +69% BMW ramp, fitness +27%, FAA-certified aviation avionics competing with Apple Watch and Honeywell.
About
Garmin Ltd. is a Olathe, Kansas-based GPS navigation and wearable technology company — publicly traded on the NASDAQ (NASDAQ: GRMN) as an S&P 500 Consumer Discretionary component, incorporated in Switzerland — designing and manufacturing GPS devices, aviation instruments, marine electronics, automotive navigation, fitness wearables, and outdoor adventure devices through approximately 21,000 employees worldwide. In fiscal year 2024, Garmin reported revenues of $6.3 billion (+18% year-over-year), with its Auto OEM segment growing 69% following the production ramp of BMW vehicle infotainment systems, and Fitness segment growing 27% on continued strength of the Forerunner, Venu, and Lily wearable lines. Garmin's diversified five-segment model (Auto, Aviation, Marine, Outdoor, Fitness) provides recession resilience — when leisure marine spending declines, aviation and fitness growth compensate — with each segment generating both hardware and recurring software/service revenue from Connect IQ app downloads, Garmin Connect subscriptions, and aviation database subscription services. CEO Cliff Pemble leads Garmin's strategy of hardware excellence in GPS-intensive applications where Apple and Samsung cannot effectively compete: Garmin's aviation GPS units (GNS, GTN, G3X avionics) are FAA-certified instruments embedded in hundreds of thousands of light aircraft cockpits, requiring Garmin-specific recertification to replace.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.